NASDAQ · CUE
Cue Biopharma, Inc.
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
Loading market information…
NASDAQ · IPSC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Century Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Century Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | $0.89+387.1% vs estimate | $109.16M+164.37% vs estimate |
|---|
| Q4 2024 | Mar 19, 2025 | -$0.43+4.44% vs estimate | $4.17M-91.58% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.37+19.57% vs estimate | $791.00K+79.77% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$0.96-$0.05 (-4.53%)
Telomir Pharmaceuticals, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 38.97% below the high.
$1.30+$0.05 (+4.0%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 42.22% below the high.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$0.88+$0.05 (+5.73%)
Karyopharm Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$0.62+$0.02 (+2.48%)
Genenta Science S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 80.32% below the high.
